Bioneer Corporation

A064550

KR7064550007

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-06 pm EDT			5-day change	1st Jan Change
29,950 ^KRW	+0.17%		-2.28%	-10.06%

Mar. 20	Bioneer Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	AFCAGRO Biotech Limited Enters into an Agreement with Bioneer Corporation to Produce Molecular Diagnostic Kits	CI

Bioneer Corporation announced that it has received KRW 18.499955 billion in funding

April 25, 2018

On April 26, 2018, Bioneer Corporation (KOSDAQ:A064550) closed the transaction.

Latest news about Bioneer Corporation

Bioneer Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
AFCAGRO Biotech Limited Enters into an Agreement with Bioneer Corporation to Produce Molecular Diagnostic Kits	Dec. 13	CI
Bioneer Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Bioneer Corporation announced that it has received KRW 999.989452 million in funding from IBK Capital Corporation	20-05-20	CI
Bioneer Corporation announced that it expects to receive KRW 999.989452 million in funding from IBK Capital Corporation	20-05-19	CI
Bioneer Corporation announced that it has received KRW 20 billion in funding from a group of investors	19-10-30	CI
Bioneer Corporation announced that it expects to receive KRW 20 billion in funding from a group of investors	19-10-27	CI
Bioneer Corporation(KOSDAQ:A064550) added to S&P Global BMI Index	18-09-24	CI
Bioneer Corporation announced that it has received KRW 18.499955 billion in funding	18-04-25	CI
Bioneer Corporation announced that it expects to receive KRW 18.499955 billion in funding	18-04-16	CI
Bioneer Corporation(KOSDAQ:A064550) dropped from S&P Global BMI Index	17-09-18	CI
Bioneer Corporation announced that it has received KRW 4.9000392 billion in funding from GK Asset Co.,Ltd.	16-10-17	CI
Bioneer Corporation announced that it expects to receive KRW 4.9000392 billion in funding from GK Asset Co.,Ltd.	16-10-13	CI
Bioneer Corporation(KOSDAQ:A064550) added to S&P Global BMI Index	16-09-19	CI
Bioneer Corporation announced that it has received KRW 5 billion in funding from LB Investment Inc., KDB Capital Corporation, Investment Arm, IBK Capital Corporation, Anda Investment Partners, and another investor.	14-04-03	CI
Bioneer Corporation announced that it expects to receive KRW 5 billion in funding from LB Investment Inc., KDB Capital Corporation, Investment Arm, IBK Capital Corporation, Anda Investment Partners, and another investor.	14-04-01	CI

BIONEER CORPORATION is a Korea-based company engaged in the biotechnology business. The Company mainly focuses on the development of deoxyribonucleic acid (DNA) reagents, molecular diagnostic kits and other services, such as DNA and ribonucleic acid (RNA) amplification products, Oligo synthesis and reagents, gene synthesis services, gene expressions, protein expressions and purifications, genomics services, human diagnostics kits, veterinary diagnostics kits and others. It also provides DNA devices, including DNA extraction, amplification and quantitative analysis devices and other DNA diagnostic devices, and supplies for tests and others. In addition, it provides equipment and supplies used for biotechnology research. The Company operates its business within domestic market and in overseas markets, including America, China, Japan, India, Africa and others.

Sector

Biotechnology & Medical Research

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIONEER CORPORATION	-10.06%	569M
REGENERON PHARMACEUTICALS, INC.	+10.44%	106B
VERTEX PHARMACEUTICALS INCORPORATED	+0.82%	104B
ARGENX SE	+6.72%	23.25B
BIONTECH SE	-13.89%	22.5B
GENMAB A/S	-6.64%	18.7B
WUXI APPTEC CO., LTD.	-37.26%	17.95B
BEIGENE, LTD.	-10.98%	16.99B
NEUROCRINE BIOSCIENCES, INC.	+8.67%	14.26B
SAREPTA THERAPEUTICS, INC.	+41.08%	12.76B

Bio Therapeutic Drugs